BMS-754807

Catalog No.S1124

BMS-754807 Chemical Structure

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Size Price Stock Quantity  
USD 180 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 14 Publications

1 Customer Review

  • Clin Cancer Res 2013 19(11), 2984-94. BMS-754807 purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.
Features Muti-inhibitor of the IGR-1R/IR family.
Targets
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
TrkB [1]
(Cell-free assay)
Met [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
1.7 nM 1.8 nM 4.1 nM 5.6 nM 7.4 nM
In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). [1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. [2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGF-Sal Ml3FT4lv[XOnIHHzd4F6 MkS4bY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCLR1[tNXIhMEmFNUCgQUAyO26PKTDhcoQhfGinIHTve45{fHKnYX2geIFz\2W2czDBb5QhMEmFNUCgQUAzOm6PKTDhcoQhVUGSSzCoTWM2OCB;IEGzcm0q NETmRlMyQTd5OECyOC=>
IGF-Sal NVfzfGZZT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYDYPJlsUUN3ME23JI5O MlrDNVk4PzhyMkS=
CCRF-CEM (ALL) MonzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYjC[GJ3hjVizszN MmPaSG1UVw>? M2PVfmlEPTB;MT6yN|kh|ryP MormNVk6QTZ{N{K=
PC3 MlnGS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXL+OUDPxE1? NV\aUXlrTE2VTx?= Mm\6TWM2OD1yLkm2OUDPxE1? NIjvTWUyQTl7NkK3Ni=>
JD Mn\aS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M33FSp42KM7:TR?= NIXURlJFVVOR MnPKTWM2OD1yLkO5NUDPxE1? MnTWNVk6QTZ{N{K=
DU145 M2nRV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVr+OUDPxE1? NWHFO|NTTE2VTx?= NUXGNJJuUUN3ME2xMlQ3PSEQvF2= MoHvNVk6QTZ{N{K=
KAG NH\sPGdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIfPcJZ,PSEQvF2= M3vU[2ROW09? NXvBeXlrUUN3ME2xMlY3PSEQvF2= MV:xPVk6PjJ5Mh?=
K-562 (CML) MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{P3UZ42KM7:TR?= M2jOOmROW09? M17JW2lEPTB;Mj6zNFIh|ryP Mn7iNVk6QTZ{N{K=
B6-P210 (Murine ALL) NYnSZ|FmT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3rufZ42KM7:TR?= M{nVPWROW09? NITDPINKSzVyPUGuNlk{KM7:TR?= MV:xPVk6PjJ5Mh?=
LN CAP-FGC M{fSTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHW2cnV,PSEQvF2= NUDybWNzTE2VTx?= M3\JRWlEPTB;MT60N|Qh|ryP MXOxPVk6PjJ5Mh?=
VW Mn\aS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWT+OUDPxE1? MUPEUXNQ MVjJR|UxRTBwMEG5JO69VQ>? NWPYe3p4OTl7OU[yO|I>
MV411 (B Myelomonocytic) MknIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUL+OUDPxE1? M4f3emROW09? NYfQN2Q{UUN3ME2wMlM{KM7:TR?= NIXp[XcyQTl7NkK3Ni=>
MDA-PCa-2b NWi4cYRTT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1LYUp42KM7:TR?= MonPSG1UVw>? MlfLTWM2OD1yLkC5PEDPxE1? M3G1WFE6QTl4Mkey
LG NGH4bXRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUPMdW5UhjVizszN MYfEUXNQ NGnxc41KSzVyPUCuNFM5KM7:TR?= M3\J[|E6QTl4Mkey
RS411 (B cell precursor-ALL) NUPQeYpxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXP+OUDPxE1? MVfEUXNQ NEXGNXBKSzVyPUCuNVAzKM7:TR?= NHHTfXMyQTl7NkK3Ni=>
22-r-1 MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFjH[lB,PSEQvF2= M4TDTWROW09? NEHEbHNKSzVyPUCuNVc2KM7:TR?= MnTtNVk6QTZ{N{K=
5838 MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUD+OUDPxE1? M{eySGROW09? NX6zSYJ4UUN3ME2wMlA{PCEQvF2= NI\r[oEyQTl7NkK3Ni=>
P388 (Murine) NVP3UYNpT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHXZO3d,PSEQvF2= M{H1R2ROW09? NELMNI5KSzVyPUSuNlch|ryP NH3vVYEyQTl7NkK3Ni=>
A2780/S NVjiNZJ2T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1XsSp42KM7:TR?= NUXSV5BYTE2VTx?= NVj1e4NzUUN3ME2wMlEzOiEQvF2= NYXBTmN3OTl7OU[yO|I>
RDES M2\0OGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3PWRp42KM7:TR?= NYq5emtPTE2VTx?= MWHJR|UxRTBwMEGyJO69VQ>? NFnMSWoyQTl7NkK3Ni=>
B6-T315I (Murine B-ALL) MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGjWTXJ,PSEQvF2= MVLEUXNQ M3\KPWlEPTB;Mj64N{DPxE1? NW\mdVd4OTl7OU[yO|I>
TOV 112D MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3qxcp42KM7:TR?= Mon0SG1UVw>? NF7OdotKSzVyPUKuNVQ3KM7:TR?= MVixPVk6PjJ5Mh?=
TC32 NGj0ZllIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3fuOZ42KM7:TR?= MYLEUXNQ MWHJR|UxRTBwMEC4JO69VQ>? NX7KWnB2OTl7OU[yO|I>
HL60 (acute myelocytic) MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NF;JO4F,PSEQvF2= M1r3UmROW09? NFzWbpBKSzVyPUCuNVIh|ryP NFrBNmsyQTl7NkK3Ni=>
TOV 21G Ml;4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmK1glUh|ryP MnTnSG1UVw>? MXfJR|UxRTRwMke5JO69VQ>? MlPKNVk6QTZ{N{K=
TC71 MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{\ybp42KM7:TR?= MlrxSG1UVw>? MlLGTWM2OD1yLkCxOEDPxE1? NIXKeIMyQTl7NkK3Ni=>
HPN-ALL (T-cell) MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVroNG9[hjVizszN M2rOeWROW09? MX;JR|UxRTBwNUKg{txO MUOxPVk6PjJ5Mh?=
A2780R MnfwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIDvVZZ,PSEQvF2= NXfVUGxOTE2VTx?= NFjQXYxKSzVyPUGuOVY1KM7:TR?= NELZfYUyQTl7NkK3Ni=>
Rh1 MmXvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHfZTGh,PSEQvF2= Ml\pSG1UVw>? MWfJR|UxRTBwMEK3JO69VQ>? Mn\4NVk6QTZ{N{K=
Kasumi-1 (acute myeloid) M4P2Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYO0Tox5hjVizszN MoL6SG1UVw>? Ml\oTWM2OD1yLkG2JO69VQ>? MoPENVk6QTZ{N{K=
sk-ov-3 MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYHHeVZLhjVizszN M4PoVWROW09? M3zkW2lEPTB;NT6xJO69VQ>? MnHGNVk6QTZ{N{K=
ME MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEnTRXR,PSEQvF2= M1PNeWROW09? MWLJR|UxRTBwMEG1JO69VQ>? NH36WZkyQTl7NkK3Ni=>
L1210 (Murine lymphocytic) M3PGUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1LmbZ42KM7:TR?= MYjEUXNQ M{HMXGlEPTB;Mj6zPUDPxE1? NH3iNFcyQTl7NkK3Ni=>
sw-626 NVT5UmhPT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYrGSoRQhjVizszN MlvESG1UVw>? MWnJR|UxRTJwM{C2JO69VQ>? M4DsNlE6QTl4Mkey
CTR NIXwVWJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUf+OUDPxE1? NF7OcmFFVVOR M4H0bGlEPTB;MD6yOVMh|ryP NVHmO|FEOTl7OU[yO|I>
ML2 (Myelomonocytic) MnjGS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MoqzglUh|ryP MlzySG1UVw>? NETkWG5KSzVyPUCuNFkh|ryP MlTTNVk6QTZ{N{K=
ovcar-3 M2LMR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NG[1ZnR,PSEQvF2= MlPZSG1UVw>? M1HofWlEPTB;NTFOwG0> NWS1Z3NGOTl7OU[yO|I>
Rh36 M3Ple2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NIDNSmJ,PSEQvF2= MX\EUXNQ NYThclhSUUN3ME2xMlQ{OiEQvF2= M33DRlE6QTl4Mkey
MOLM-13 (acute myeloid) M1jNb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHXGSFl,PSEQvF2= MUnEUXNQ Mo\0TWM2OD1yLkSyJO69VQ>? NGrjZlgyQTl7NkK3Ni=>
ovcar-4 NXm1ZopRT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NX;qOZd5hjVizszN MlvkSG1UVw>? MYjJR|UxRTFizszN MmHtNVk6QTZ{N{K=
Rh41 NWriNGlqT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGDzb2J,PSEQvF2= MknRSG1UVw>? MnfkTWM2OD1yLkCwOUDPxE1? MoL0NVk6QTZ{N{K=
Mutz 2 (acute myeloid) M{LZfmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MY\+OUDPxE1? Mle2SG1UVw>? NWm1e|hRUUN3ME2xMlE2KM7:TR?= M2XJ[VE6QTl4Mkey
ovcar-5 M3TaXmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYGxU49qhjVizszN NFrueoJFVVOR Mnf0TWM2OD1yLkC1JO69VQ>? NGTieGMyQTl7NkK3Ni=>
RD1 NHv0XpdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmLLglUh|ryP MkS3SG1UVw>? MWLJR|UxRTBwME[4JO69VQ>? NFr2SXcyQTl7NkK3Ni=>
OCI-AML 2 (acute myeloid) MmDFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NX\5VoJthjVizszN NFu5cJFFVVOR M1\CU2lEPTB;Mz6zN{DPxE1? MVexPVk6PjJ5Mh?=
786-O NWfIXYViT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFnVfoh,PSEQvF2= Mkn0SG1UVw>? MWDJR|UxRTFwNkS3JO69VQ>? M1;RUVE6QTl4Mkey
A673 Ml;1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWLMPWU4hjVizszN M4\2XGROW09? MX3JR|UxRTBwNEC4JO69VQ>? MnvKNVk6QTZ{N{K=
TALL-1 (T-cell) MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4jxcZ42KM7:TR?= NH7lUpdFVVOR M3TnVWlEPTB;MT6yPEDPxE1? NULlTI5JOTl7OU[yO|I>
151-B MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVn+OUDPxE1? M2PoXWROW09? NFjl[|BKSzVyPUKuOlch|ryP NEeyOWoyQTl7NkK3Ni=>
PFSK-1 NEK3doRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1TxfJ42KM7:TR?= M4nOW2ROW09? NUPG[2RTUUN3ME2wMlE{OiEQvF2= M2XITlE6QTl4Mkey
THP-1 MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MX7+OUDPxE1? NYfMOFdWTE2VTx?= MoHBTWM2OD14LkW4JO69VQ>? NEDhOWwyQTl7NkK3Ni=>
HEK293 NXj1fGt1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHjlR2h,PSEQvF2= MnO2SG1UVw>? NHXuPZRKSzVyPUCuPVE2KM7:TR?= MmCzNVk6QTZ{N{K=
DAOY M1SwVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1izep42KM7:TR?= NXzje40xTE2VTx?= M2rFSmlEPTB;MT65O|kh|ryP M2GxOlE6QTl4Mkey
SET2 NYPYOoxjT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2XxN542KM7:TR?= M2HtPGROW09? M2D5Z2lEPTB;MD6yPVgh|ryP NXe0fYxMOTl7OU[yO|I>
HTB-46 NITMcJRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3PRep42KM7:TR?= M1\XOWROW09? Moq2TWM2OD13LkK1JO69VQ>? NX;3copSOTl7OU[yO|I>
SK-NAS M1HGdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkS2glUh|ryP NGS1WZVFVVOR MnrCTWM2OD1yLkS5O{DPxE1? NVqwWVM6OTl7OU[yO|I>
CTLL2 NVnWfVZyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoThglUh|ryP NEK0bJJFVVOR NYLvOpV3UUN3ME6xMlAxKM7:TR?= MY[xPVk6PjJ5Mh?=
HTB-47 MonVS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFrlRY9,PSEQvF2= NX7nW2w4TE2VTx?= MkT0TWM2OD1{LkC1OkDPxE1? MkHONVk6QTZ{N{K=
LAN-1 Ml7oS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVjNeIxOhjVizszN M3fldmROW09? NYP4NlRtUUN3ME2wMlA1KM7:TR?= MWixPVk6PjJ5Mh?=
ST486 MknkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFjCPHd,PSEQvF2= NV3qUGRFTE2VTx?= NFjDc3dKSzVyPUGuNVkh|ryP MVqxPVk6PjJ5Mh?=
HS766T NG\yW|ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{\MdZ42KM7:TR?= M3XJPWROW09? NEHTeFFKSzVyPUKuNFAyKM7:TR?= MoXiNVk6QTZ{N{K=
IMR-32 M3TOb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnX0glUh|ryP NUf1fVV7TE2VTx?= NYDGZZJHUUN3ME2wMlI3OSEQvF2= NWPuNoR6OTl7OU[yO|I>
Daudi (Burkitt's) M2CzWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUf+OUDPxE1? MVfEUXNQ M1:0eGlEPTB;Mj62N|ch|ryP MWexPVk6PjJ5Mh?=
Aspc-1 MmLrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmToglUh|ryP NH70TlhFVVOR Ml7xTWM2OD1yLkO3PUDPxE1? MVSxPVk6PjJ5Mh?=
SK-NSH NULseZVIT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHXBZot,PSEQvF2= NXrmUmN1TE2VTx?= M1LhbmlEPTB;MD6xN|kh|ryP M2rjU|E6QTl4Mkey
MEC-1 (Chronic B cell) NXXlfXl5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M17oSJ42KM7:TR?= NUnuNFFsTE2VTx?= M3TB[GlEPTB;Mj62N|ch|ryP MoG2NVk6QTZ{N{K=
Capan-2 Ml62S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NELVUIN,PSEQvF2= MYrEUXNQ NWnj[5I2UUN3ME2xMlc4PCEQvF2= MWexPVk6PjJ5Mh?=
SHSY5Y NEnye5BIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M17lTJ42KM7:TR?= NXTFRotWTE2VTx?= NI\HUlFKSzVyPUCuNVA3KM7:TR?= Ml33NVk6QTZ{N{K=
U937 (Histioocytic) MV\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVm2e3FqhjVizszN MUHEUXNQ MVXJR|UxRjVwMECg{txO NEHwTmEyQTl7NkK3Ni=>
Bxpc-1 NFz2S2ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1r4[p42KM7:TR?= NHzUWlFFVVOR NXzDO4JmUUN3ME2xMlkzPCEQvF2= NHnZeWkyQTl7NkK3Ni=>
Bxpc-3 NY[wbHRHT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVT+OUDPxE1? NULWTpFxTE2VTx?= NFflRY9KSzVyPkWuNFAh|ryP NXLs[4prOTl7OU[yO|I>
HTB-92 NH\I[pBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Ml2xglUh|ryP Mn3vSG1UVw>? M{PqfmlEPTB;MT6wNkDPxE1? NVfXNYZsOTl7OU[yO|I>
OCI-LY10 (B-cell) NFLwXIdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NG\pZWp,PSEQvF2= Mm\wSG1UVw>? NWPXeYhUUUN3ME2wMlQ2KM7:TR?= NGLZWZEyQTl7NkK3Ni=>
PANC-1 MnvKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M{Tu[J42KM7:TR?= NUPjRWRmTE2VTx?= MlfQTWM2OD53LkCwJO69VQ>? M3vQ[FE6QTl4Mkey
To184.T NYK0XVhFT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{P0Up42KM7:TR?= Ml7ESG1UVw>? NWLvcph1UUN3ME2wMlQ3QSEQvF2= NXrXepRmOTl7OU[yO|I>
OCI-LY19 (B-cell) NHLm[2dIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NI\4V4N,PSEQvF2= MoTrSG1UVw>? MWHJR|UxRTBwNDFOwG0> Mo\SNVk6QTZ{N{K=
PANC-1 BM MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2q3UZ42KM7:TR?= MX7EUXNQ MYPJR|UxRjVwMECg{txO MYexPVk6PjJ5Mh?=
SA-4 NELabo5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUD+OUDPxE1? NETWd|dFVVOR MnzWTWM2OD1zLkOwNUDPxE1? MV2xPVk6PjJ5Mh?=
RPMI 8226 M3nMRWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlviglUh|ryP MUTEUXNQ NVfJ[oR2UUN3ME2xMlI6OyEQvF2= MUixPVk6PjJ5Mh?=
HPAF-II M4rnUWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2LF[p42KM7:TR?= NHTzfWNFVVOR MVvJR|UxRTBwNkS0JO69VQ>? M1zEU|E6QTl4Mkey
SHP-77 MUXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MoK5glUh|ryP MnzYSG1UVw>? NXjUTGtuUUN3ME2xMlg5QCEQvF2= MWSxPVk6PjJ5Mh?=
U266 B1 MmnvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHjsT2J,PSEQvF2= Mni4SG1UVw>? NVPGcoNDUUN3ME2xMlY3QSEQvF2= NXnkUXd4OTl7OU[yO|I>
Hs700t M{XjZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHPFV4F,PSEQvF2= MofMSG1UVw>? NFTOT5ZKSzVyPUCuNlMyKM7:TR?= NHz0SXYyQTl7NkK3Ni=>
NCI-446 NYPoeZhGT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2X6Up42KM7:TR?= MX\EUXNQ M2DTT2lEPTB;MT6xOVQh|ryP MXKxPVk6PjJ5Mh?=
H929 M4T0emdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHTrb2d,PSEQvF2= MkD6SG1UVw>? NIPvRmxKSzVyPUCuNFE1KM7:TR?= NILRN2syQTl7NkK3Ni=>
PL45 NUjifoFHT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX3+OUDPxE1? NGHX[GhFVVOR M2DHdmlEPTB;Mj6yOVUh|ryP NVnSZWFROTl7OU[yO|I>
NCI-H383 NG\z[nJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGTlSHV,PSEQvF2= M4rUN2ROW09? MnXyTWM2OD53LkCwJO69VQ>? MWixPVk6PjJ5Mh?=
JJN3 NYe5RYFXT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVK4OoFXhjVizszN MkPvSG1UVw>? M4DlZWlEPTB;Mj60N|Mh|ryP NVjWNXpmOTl7OU[yO|I>
SU.86.86 NGHaNnpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlO1glUh|ryP M2n2XGROW09? MU\JR|UxRTJwNkeyJO69VQ>? NHXxTlkyQTl7NkK3Ni=>
H1299 NEDRfWVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHTY[Gp,PSEQvF2= MkTBSG1UVw>? MWLJR|UxRjVwMECg{txO M3npXlE6QTl4Mkey
MDA-MB-468 NVnvPXh3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NInKNXJ,PSEQvF2= MlmxSG1UVw>? M3PRXmlEPTB;MD61NFQh|ryP MlPsNVk6QTZ{N{K=
SW1990 MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIDGNm5,PSEQvF2= MkK0SG1UVw>? MUPJR|UxRTBwOEK2JO69VQ>? NUnvVXE{OTl7OU[yO|I>
Calu-6 MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXz+OUDPxE1? NYTnfpZoTE2VTx?= NYfv[HVRUUN3ME61MlAxKM7:TR?= M3nEflE6QTl4Mkey
MDA-MB-231 NWDHPXBVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFW1e4l,PSEQvF2= NYm0cW5jTE2VTx?= M{HySGlEPTB;MT62OFgh|ryP MVixPVk6PjJ5Mh?=
SW-684 MmO4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MX3+OUDPxE1? Mk\XSG1UVw>? M3K5d2lEPTB-NT6wNEDPxE1? NFHKXWcyQTl7NkK3Ni=>
H209 NXGzc4NKT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGrLcJR,PSEQvF2= NWjNWpFrTE2VTx?= NWS1XlNWUUN3ME2xMlE6OyEQvF2= NYjuO|FKOTl7OU[yO|I>
MDA-MB-231T MmjKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1z1V542KM7:TR?= NFf2ephFVVOR M4f6WWlEPTB-NT6wNEDPxE1? NGnTXmYyQTl7NkK3Ni=>
HT1080/S NIG5d4RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MonRglUh|ryP NUiwbng3TE2VTx?= MonkTWM2OD1yLkWzNUDPxE1? NWTLNIRjOTl7OU[yO|I>
H526 0.044 M3X5VGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWrZfW1QhjVizszN NF;JdWlFVVOR MVPJR|UxRTBwMES0JO69VQ>? M1zDUFE6QTl4Mkey
DU4475 2.431 MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mli5glUh|ryP MmfkSG1UVw>? NEn6T2FKSzVyPUKuOFMyKM7:TR?= MV[xPVk6PjJ5Mh?=
HCT116 NWP4[Y96T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFi4O2N,PSEQvF2= NFrNSXpFVVOR NGXjdVZKSzVyPUCuPFUzKM7:TR?= NULXZVVtOTl7OU[yO|I>
M109 MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mo\DglUh|ryP MV7EUXNQ M1PLWWlEPTB;MT6wOVUh|ryP NFHvXmkyQTl7NkK3Ni=>
BT549 MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYjZNoFnhjVizszN M3\JcGROW09? MX;JR|UxRTFwNkS1JO69VQ>? NYrQNlAxOTl7OU[yO|I>
HCT116/VM46 MmnoS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3ixN542KM7:TR?= NF7jSYxFVVOR NEK4XWdKSzVyPUGuO|AzKM7:TR?= MVKxPVk6PjJ5Mh?=
H460 Ml7kS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVT+OUDPxE1? MXfEUXNQ Mo\CTWM2OD1yLke5OUDPxE1? NFTsPXEyQTl7NkK3Ni=>
MCF-7 NUXZXZh5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NULEVGMyhjVizszN M2roOGROW09? M2L6PWlEPTB;MD6wNVYh|ryP MVixPVk6PjJ5Mh?=
GEO NEC2PJRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVT+OUDPxE1? NYr4O4ZOTE2VTx?= MkT0TWM2OD1yLkO1OkDPxE1? NH\ycWQyQTl7NkK3Ni=>
H441 0.646 MnrvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVn+OUDPxE1? MUXEUXNQ NYi4U4JIUUN3ME2wMlY1PiEQvF2= NELhVmYyQTl7NkK3Ni=>
MCF-7-807R M{jSU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NW\xdI1phjVizszN NHzrbZdFVVOR NWjmOml5UUN3ME2wMlQ6KM7:TR?= M3Lld|E6QTl4Mkey
Colo205 MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXrYdJM{hjVizszN NVjQdHdpTE2VTx?= NXrsZpJRUUN3ME2wMlExPCEQvF2= NIXLbnEyQTl7NkK3Ni=>
H292 Ml3LS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmT2glUh|ryP NH[1eoFFVVOR MX\JR|UxRTBwN{i4JO69VQ>? NVnqVFdqOTl7OU[yO|I>
BT474 (S) MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIrIS5B,PSEQvF2= MWTEUXNQ NV73d4F7UUN3ME2yMlQxOyEQvF2= M1nOc|E6QTl4Mkey
HT-29 MmLnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnTTglUh|ryP MlLySG1UVw>? MY\JR|UxRTJwMUCzJO69VQ>? M2DEOVE6QTl4Mkey
A549 NY\lOlBnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoX5glUh|ryP NWPFSHBlTE2VTx?= NUD0cY9VUUN3ME2wMlY4PSEQvF2= MVWxPVk6PjJ5Mh?=
BT474-M1 M1j3bGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXnJengyhjVizszN M3KwWmROW09? M3j4RWlEPTB;Mj6zOlUh|ryP NV;icGdUOTl7OU[yO|I>
SW480 NIf3epRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3LVbJ42KM7:TR?= M3G4S2ROW09? MUDJR|UxRjVwMECg{txO MoPYNVk6QTZ{N{K=
L2987 MoPyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXv+OUDPxE1? NY\XO3ZwTE2VTx?= NHzweXpKSzVyPUCuOFQzKM7:TR?= M{f3flE6QTl4Mkey
AU565 NXzNWlZyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUn+OUDPxE1? M3PXbWROW09? M{XHW2lEPTB;ND65O{DPxE1? M4DPcVE6QTl4Mkey
SW403 NUPReGZFT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkPiglUh|ryP MlXxSG1UVw>? MXXJR|UxRTBwMkKg{txO MmW5NVk6QTZ{N{K=
H1437 MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXX+OUDPxE1? Mo\HSG1UVw>? MoXxTWM2OD1yLkWyN{DPxE1? NF2ybnMyQTl7NkK3Ni=>
BT-20 NXXsV|huT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYP+OUDPxE1? NULDdXU1TE2VTx?= M176[2lEPTB;Mz61OlIh|ryP NYK5ZVlxOTl7OU[yO|I>
Colo320HSR MmDYS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFn2PZN,PSEQvF2= M1;4XWROW09? M{jCOWlEPTB;MD6wNVEh|ryP MVKxPVk6PjJ5Mh?=
H2087 NEHDWIxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGHWTI9,PSEQvF2= NXHUWHdUTE2VTx?= MXnJR|UxRjFwMECg{txO M{jQflE6QTl4Mkey
HCC1419 NUnDNHV5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlnTglUh|ryP NXPFXnFlTE2VTx?= NHfDd3lKSzVyPUKuOVE4KM7:TR?= MX2xPVk6PjJ5Mh?=
WiDr M2iwdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M13rWp42KM7:TR?= Mk[5SG1UVw>? M3\I[GlEPTB;MD6wO|Yh|ryP M4jZRVE6QTl4Mkey
H661 0.573 NXvVXItST3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEHZ[JB,PSEQvF2= Mon4SG1UVw>? MUfJR|UxRTBwNUezJO69VQ>? MWCxPVk6PjJ5Mh?=
HCC-38 MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{C5dp42KM7:TR?= MYjEUXNQ MX\JR|UxRjVwMECg{txO MXGxPVk6PjJ5Mh?=
LS174T NWPFOmpOT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M33sZ542KM7:TR?= NVzZWFhrTE2VTx?= MYHJR|UxRTBwNUO1JO69VQ>? MoD2NVk6QTZ{N{K=
H211 MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NX3tOXI{hjVizszN MYnEUXNQ MlvyTWM2OD1yLkezN{DPxE1? NXrwcXNVOTl7OU[yO|I>
HCC70 MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4mwN542KM7:TR?= NGLBPHRFVVOR MYLJR|UxRTFwNUWg{txO NYTXdFFxOTl7OU[yO|I>
SW116 NVPNcpE4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1XpVZ42KM7:TR?= NFzZeVBFVVOR MYTJR|UxRTBwME[3JO69VQ>? MoXVNVk6QTZ{N{K=
H513 M4iyTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3uyUJ42KM7:TR?= NIjtV3dFVVOR NYrHVnVqUUN3ME20MlQ1QCEQvF2= MV[xPVk6PjJ5Mh?=
MDA-MB-157 NYDvWVVMT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXPpenNFhjVizszN MV;EUXNQ M3XKc2lEPTB;MD6wN|Yh|ryP MmnkNVk6QTZ{N{K=
H2052 M{fRWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUH+OUDPxE1? NGnXOXVFVVOR NUSxe2lOUUN3ME2xMlA2KM7:TR?= MmDMNVk6QTZ{N{K=
MDA-MB-415 NXzndoFsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoDyglUh|ryP Ml7iSG1UVw>? MmfMTWM2OD53LkCwJO69VQ>? M2DKXVE6QTl4Mkey
DLD-1 MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYP+OUDPxE1? MnK3SG1UVw>? Mn\CTWM2OD1yLkmwPUDPxE1? NI\SXo8yQTl7NkK3Ni=>
H2595 NHixcmdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MU\+OUDPxE1? MYHEUXNQ NFLYbXBKSzVyPUSuOFc2KM7:TR?= MofONVk6QTZ{N{K=
MDA-MB-435S M2PHU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnO4glUh|ryP MoWzSG1UVw>? M4H2fWlEPTB;MT64Olkh|ryP M1TIfFE6QTl4Mkey
HCT15 NVPMZXdMT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX\+OUDPxE1? MYXEUXNQ NVzjS2RqUUN3ME6xMlAxKM7:TR?= NVnLZ2xvOTl7OU[yO|I>
SK-Hep1 M2[yemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWP+OUDPxE1? MYLEUXNQ NFrJR|FKSzVyPUCuNVQ3KM7:TR?= MYmxPVk6PjJ5Mh?=
MDA-MB-436 M4OzdGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlS1glUh|ryP MX\EUXNQ Mlr6TWM2OD13LkWwNkDPxE1? NEDtb5oyQTl7NkK3Ni=>
KM12C NVjqXW15T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2j5eJ42KM7:TR?= MlX6SG1UVw>? M1HkXGlEPTB;MD6wOVQh|ryP M12yW|E6QTl4Mkey
HEPG2 MlrvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWj+OUDPxE1? MY\EUXNQ M4jQeWlEPTB;MD6wNlUh|ryP MUCxPVk6PjJ5Mh?=
MDA-MB-453 NVnzd4N2T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2n5b542KM7:TR?= NEXvZYRFVVOR Ml\rTWM2OD1zLki2PUDPxE1? Mn7KNVk6QTZ{N{K=
KM12SM NYHXN2RYT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkTMglUh|ryP MkXRSG1UVw>? M2TybWlEPTB;MD6wOVkh|ryP MVWxPVk6PjJ5Mh?=
1483 M4\USmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NV\SfpIzhjVizszN MYrEUXNQ Ml3pTWM2OD1{LkG5JO69VQ>? MWSxPVk6PjJ5Mh?=
Hs578t MlfnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWP2N3N7hjVizszN NES2bIxFVVOR MnmyTWM2OD1zLkK4O{DPxE1? NVuzcYdMOTl7OU[yO|I>
LS180 MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NV\ESlJRhjVizszN M3;Kc2ROW09? NVX6bpNYUUN3ME2wMlY6PiEQvF2= MkD5NVk6QTZ{N{K=
FaDu MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4LuUJ42KM7:TR?= MWTEUXNQ M3zaPGlEPTB;MT6yO{DPxE1? NUnieVRyOTl7OU[yO|I>
ZR-75-1 NXvUbpk1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MofPglUh|ryP NYn0R2w{TE2VTx?= MXzJR|UxRTJwMEi0JO69VQ>? M4jtbVE6QTl4Mkey
LS513 MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MlzFglUh|ryP NVHPVlQxTE2VTx?= NI\aO4hKSzVyPUCuNVM2KM7:TR?= NEDBdZIyQTl7NkK3Ni=>
Detroit.562 MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2nTXp42KM7:TR?= NGjOUGVFVVOR NXvKU4pvUUN3ME2xMlE1KM7:TR?= M3qzcVE6QTl4Mkey
ZR-75-30 MljpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlfjglUh|ryP NGS1U3pFVVOR NUHtc4J4UUN3ME61MlAxKM7:TR?= NVzKcIdROTl7OU[yO|I>
RKO-PM MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXXMdmhkhjVizszN NEP2VphFVVOR M2PzUmlEPTB;MD6yN|Ih|ryP NE\X[WwyQTl7NkK3Ni=>
Cal.27 M1LTU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHTObmt,PSEQvF2= MoD5SG1UVw>? Moj0TWM2OD1{IN88US=> NGTGeoUyQTl7NkK3Ni=>
KPL4 NFLWfGNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4HT[Z42KM7:TR?= MlnnSG1UVw>? M4Dlc2lEPTB;MT6yOVIh|ryP NFvFOXYyQTl7NkK3Ni=>
PKO-RM13 M1TwPWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NG\qTnJ,PSEQvF2= MoLRSG1UVw>? MoDiTWM2OD1yLkSyOUDPxE1? MnvJNVk6QTZ{N{K=
HS.53.T M3H1R2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYnKT|NRhjVizszN NHzwPZlFVVOR Ml;oTWM2OD1yLke5JO69VQ>? NE\wTGkyQTl7NkK3Ni=>
EMT6 NH3Ue3RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2HJXJ42KM7:TR?= MVvEUXNQ NFTHSJBKSzVyPUCuPFA3KM7:TR?= MVuxPVk6PjJ5Mh?=
SNU-C1 M4PZ[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1XPPJ42KM7:TR?= NXH0XYhqTE2VTx?= NX;EU|BtUUN3ME2wMlAxPyEQvF2= NELzXVEyQTl7NkK3Ni=>
SQCCY1 MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYn6TWx[hjVizszN NF\SSW9FVVOR MnzlTWM2OD1yLke5JO69VQ>? NHzodZMyQTl7NkK3Ni=>
SW480 NHfXUnlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYn+OUDPxE1? MnX0SG1UVw>? NFfkWG5KSzVyPUCuNFM4KM7:TR?= M1zCZlE6QTl4Mkey
SCC9 M2HONmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYL+OUDPxE1? NXvQPWFKTE2VTx?= MnrZTWM2OD1yLke1JO69VQ>? MoeyNVk6QTZ{N{K=
SK-LMS-1 NEDzdFVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWD+OUDPxE1? MULEUXNQ MoTGTWM2OD1yLk[4O{DPxE1? MkC1NVk6QTZ{N{K=
SCC25 Mn7TS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmjvglUh|ryP NVXsXJFQTE2VTx?= MlPsTWM2OD1yLk[4JO69VQ>? M3OwbVE6QTl4Mkey
U87 Mon2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MonWglUh|ryP MY\EUXNQ MkDwTWM2OD1yLkm1JO69VQ>? MYKxPVk6PjJ5Mh?=
SCC15 NGLRWIxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYT+OUDPxE1? MVnEUXNQ MV7JR|UxRTBwNkeg{txO MXOxPVk6PjJ5Mh?=
T98G MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MWH+OUDPxE1? MULEUXNQ M3TGNmlEPTB;MT6yNVgh|ryP MWWxPVk6PjJ5Mh?=
SCC4 MnjFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MoriglUh|ryP NIDrOYhFVVOR M1;D[GlEPTB;MD62N{DPxE1? M13wUVE6QTl4Mkey
U118 MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHPJcol,PSEQvF2= NHjhW4lFVVOR M3XOdmlEPTB;MT62NVgh|ryP M1THbVE6QTl4Mkey
TU167 MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1\iUJ42KM7:TR?= NWT3fFFFTE2VTx?= M4jPNGlEPTB;ND61NkDPxE1? NX3ER2lrOTl7OU[yO|I>
NCI-H727 M4HCZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mn;hglEx6oDMzszN MWnEUXNQ NUfUSm5iUUN3ME20Nlghdk1? MlPvNlA{QDV5NEe=
NCI-H720 MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2HUSJ4yOOLCit88US=> M4\BOmROW09? MkjDTWM2OD1{Lkig{txO NWXscJAzOjB|OEW3OFc>
NCI-H835 NVrWdZh7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWO5XFBShjFy4pEK{txO MU\EUXNQ M1;zc2lEPTB;MTFOwG0> M1n4OFIxOzh3N{S3
NCI-H727 Mk\TT4lv[XOnIHHzd4F6 MV;+NVDjiIsQvF2= MnvvSG1UVw>? M4XZcYlvcGmkaYTzJINwdnO2aYT1eIl3\SCLR1[xVkBifXSxcHjvd5Bpd3K7bHH0bY9v MVqyNFM5PTd2Nx?=
RD NGr0[olIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1zpbp4yOOLCit88US=> NVnINYtHUUN3ME2xMlEzKML3TR?= NEfsW3YzOTJ7OEe0OS=>
Rh41 M2rRNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFPibpN,OTEkgJtOwG0> MorRTWM2OD1yLkC3JOK2VQ>? NVWwUGtsOjF{OUi3OFU>
Rh18 NFjmcFFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWL+NVDjiIsQvF2= MnHvTWM2OD12Lkm2JOK2VQ>? NX;FdWo4OjF{OUi3OFU>
Rh30 M2S3PGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mkj3glEx6oDMzszN NXfiSZhUUUN3ME2wMlE6KML3TR?= NWDKUJZKOjF{OUi3OFU>
BT-12 MkXRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mkf1glEx6oDMzszN NEixfnZKSzVyPUCuO|ghyrWP MXuyNVI6QDd2NR?=
CHLA-266 MX7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXLVVHRXhjFy4pEK{txO NET2epFKSzVyPUCuPFkhyrWP M{D2clIyOjl6N{S1
TC-71 M4LBWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYr+NVDjiIsQvF2= MWDJR|UxRTBwMUGgxtVO Mmf4NlEzQTh5NEW=
CHLA-9 M3jp[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXXCR2M4hjFy4pEK{txO MW\JR|UxRTBwMUKgxtVO NYHsUGhCOjF{OUi3OFU>
CHLA-10 MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEHVfWp,OTEkgJtOwG0> M2O3XWlEPTB;MD62NkDDvU1? M33VTVIyOjl6N{S1
CHLA-258 NWjjUJBkT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1;W[Z4yOOLCit88US=> NXzQNmZQUUN3ME2wMlI4KML3TR?= NFvLb4gzOTJ7OEe0OS=>
GBM2 NV\5V3VHT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlfKglEx6oDMzszN MlLDTWM2OD1zLkS3JOK2VQ>? MkjJNlEzQTh5NEW=
NB-1643 MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUX+NVDjiIsQvF2= M1fFXGlEPTB;MD6xNkDDvU1? NH20cG4zOTJ7OEe0OS=>
NB-EBc1 MlfJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mnn3glEx6oDMzszN M2\PRmlEPTB;MD6zOUDDvU1? MYCyNVI6QDd2NR?=
CHLA-90 NUDyPJYyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEfuVnZ,OTEkgJtOwG0> Mln4TWM2OD1yLke3JOK2VQ>? MnjCNlEzQTh5NEW=
CHLA-136 NUjPZXplT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoW3glEx6oDMzszN NWX5XItOUUN3ME2wMlUzKML3TR?= Mn23NlEzQTh5NEW=
NALM-6 MlzsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MoHLglEx6oDMzszN Mnu4TWM2OD1yLkS5JOK2VQ>? Mn7pNlEzQTh5NEW=
COG-LL-317 NH3L[pJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Ml\3glEx6oDMzszN MYTJR|UxRTFwM{igxtVO MYGyNVI6QDd2NR?=
RS4;11 Mn7NS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUj0XIozhjFy4pEK{txO MofDTWM2OD1yLkO4JOK2VQ>? NWrld|VROjF{OUi3OFU>
MOLT-4 M2rL[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWf3TWtRhjFy4pEK{txO M{TlV2lEPTB;MD61N{DDvU1? NGLVT2QzOTJ7OEe0OS=>
CCRF-CEM Mn3CS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHrBNId,OTEkgJtOwG0> MWTJR|UxRTFwMUOgxtVO MlzzNlEzQTh5NEW=
Kasumi-1 MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2L2ZZ4yOOLCit88US=> NFm1O2lKSzVyPUGuNkDDvU1? M{fkb|IyOjl6N{S1
Karpas-299 Mn7TS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnOxglEx6oDMzszN NYC3Zms5UUN3ME2xMlY1KML3TR?= MXmyNVI6QDd2NR?=
Ramos-RA1 NXzxZ2hkT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkTRglEx6oDMzszN MoHtTWM2OD1zLkOxJOK2VQ>? MVKyNVI6QDd2NR?=
Rh30  NF3HbVBHfW6ldHnvckBie3OjeR?= NF;pW5ZqdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:|cHjvdplt[XSrb36= M37TU|I2QTJ3M{e4
Rh41 M3jsOmZ2dmO2aX;uJIF{e2G7 NWTwR45ucW6mdXPld{BidiCrbnPy[YF{\SCxZjDTSmsheGixc4Doc5J6dGG2aX;u MXSyOVkzPTN5OB?=
RD MVLGeY5kfGmxbjDhd5NigQ>? MnLFbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w Ml;DNlU6OjV|N{i=
A549 MVzLbY5ie2ViYYPzZZk> M2rR[lAvPeLCit88US=> MYjEUXNQ M2DlfYlvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v NWDp[nVSOjZ7Mki1O|g>
NCI-H358 M3zJdWtqdmG|ZTDhd5NigQ>? M3vZXVAvPeLCit88US=> MWXEUXNQ NX7ofXFZcW6qaXLpeJMhUUeILVnSM2lTKGGldHn2ZZRqd25? Mlv0NlY6Ojh3N{i=
A549 MlT6SpVv[3Srb36gZZN{[Xl? NYT1[HZYOC534pEK{txO Mm\lSG1UVw>? M1zyXoNifXOnczDhJINwdmO3coLlcpQh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHHu[EBGWkt? MkLGNlY6Ojh3N{i=
NCI-H358 M3zhfmZ2dmO2aX;uJIF{e2G7 MmLZNE426oDMzszN MnvNSG1UVw>? NFyyOGtk[XW|ZYOgZUBkd26ldYLy[Y51KGSnY4LlZZNmKGmwIIDoc5NxcG:{eXzheIVlKEGNVDDhcoQhTVKN M2H2TFI3QTJ6NUe4
A549 NF7STXlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGm3emF,OTEkgJtOwG0> NY\r[oZQTE2VTx?= NXTRTm84UUN3ME2wMlc3KM7:TR?= M3rkTVI3QTJ6NUe4
NCI-H358 NXfKVFZ5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHrGdJp,OTEkgJtOwG0> NUHYS2J[TE2VTx?= NHrwdGhKSzVyPUGuNFkh|ryP MYqyOlkzQDV5OB?=
A549 NFf5foVCeG:ydH;zbZMh[XO|YYm= NELH[5kxNjYkgJtOwG0> MoDqSG1UVw>? MknEbY5lfWOnczDBdI9xfG:|aYO= Ml2yNlY6Ojh3N{i=
NCI-H358 NH\mOoxCeG:ydH;zbZMh[XO|YYm= NF70[W0xNjYkgJtOwG0> M2i2e2ROW09? MWjpcoR2[2W|IFHwc5B1d3Orcx?= NGnnOHMzPjl{OEW3PC=>
A549 NX;GO3JWTnWwY4Tpc44h[XO|YYm= NGiyW|MxNjYkgJtOwG0> M3PYVGROW09? MkjLdoVlfWOnczD3c5Vv\CClbH;zeZJm MVyyOlkzQDV5OB?=
NCI-H358 NHW4b3lHfW6ldHnvckBie3OjeR?= Mnr1NE426oDMzszN M3XE[2ROW09? NV;LZ4pXemWmdXPld{B4d3WwZDDjcI9{fXKn NX76WmQ6OjZ7Mki1O|g>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 26136493     


(C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.

26136493
Growth inhibition assay
Cell viability; 

PubMed: 30754629     


Response of SK-CO-1 to various drugs and drug combinations.

30754629
In vivo BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. [1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. [2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. [3]

Protocol

Kinase Assay:[1]
- Collapse

Kinase inhibition assays:

The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to Km ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:[1]
- Collapse
  • Cell lines: IGF-1R-Sal, RH41 and Geo cell lines
  • Concentrations: 365 nM
  • Incubation Time: 72 hours
  • Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of 3H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice
  • Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol)
  • Dosages: 150 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 92 mg/mL (199.35 mM)
Ethanol 92 mg/mL (199.35 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.49
Formula

C23H24FN9O

CAS No. 1001350-96-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy BMS-754807 | BMS-754807 supplier | purchase BMS-754807 | BMS-754807 cost | BMS-754807 manufacturer | order BMS-754807 | BMS-754807 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID